Welcome to our dedicated page for Bio-Path Hldgs news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Hldgs stock.
Bio-Path Holdings, Inc. (BPTH) generates frequent news as a clinical-stage biotechnology company developing RNAi nanoparticle drugs using its proprietary DNAbilize® liposomal antisense platform. Company announcements focus on progress across its oncology and obesity programs, including clinical trial updates, preclinical data, intellectual property developments, and corporate actions.
News coverage commonly highlights the Phase 2 trial of prexigebersen (BP1001) in acute myeloid leukemia and other blood cancers, where Bio-Path has reported extended treatment durability and complete remissions in elderly AML patients treated with combinations that include prexigebersen. Regular updates also cover the Phase 1/1b trial of BP1001-A in advanced solid tumors, including reports of tumor reduction and stable disease in heavily pretreated gynecologic cancer patients.
Another recurring theme in BPTH news is the exploration of BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. Press releases describe preclinical studies in muscle and liver cell models showing improved insulin sensitivity and restored insulin signaling, along with milestones in the path toward an Investigational New Drug (IND) application.
Investors following BPTH news will also see updates on BP1002 for relapsed or refractory AML, including venetoclax-resistant patients, and BP1003 targeting STAT3, as well as reports on patent issuances that expand the company’s DNAbilize® intellectual property portfolio. In addition, SEC filings and corporate press releases provide information on financing efforts, operational pauses, leadership changes, and the company’s transition from Nasdaq listing to trading on over-the-counter markets. This news page aggregates these developments so readers can track Bio-Path’s clinical, scientific, and corporate trajectory over time.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its Q3 2020 financial results, reporting a net loss of $3.0 million ($0.80 per share), an increase from $2.2 million ($0.78 per share) in Q3 2019. R&D expenses rose to $2.0 million due to Phase 2 trial enrollment for prexigebersen in AML. The company has $12.1 million in cash remaining and raised approximately $4.6 million through a stock offering post-Q3. Significant advancements include the initiation of the first patient in Stage 2 of the Phase 2 trial for AML and a strategic patent allowance for prexigebersen.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a conference call and audio webcast on November 13, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020. The company specializes in developing cancer treatments using its DNAbilize® antisense RNAi nanoparticle technology. Its lead candidate, prexigebersen (BP1001), is advancing in a Phase 2 study for blood cancers, while prexigebersen-A is being considered for Phase 1 trials in solid tumors. Details for accessing the call are provided in the announcement.
Bio-Path Holdings (NASDAQ: BPTH) announced a notice of allowance from the United States Patent and Trademark Office for claims related to its lead product candidate, prexigebersen, in combination with certain cancer therapies. This patent enhances the company's intellectual property portfolio, providing broad protection for prexigebersen against various cancers. Currently, prexigebersen is undergoing a Phase 2 clinical trial for acute myeloid leukemia. The new patent supports ongoing investments in this treatment option for patients with limited alternatives.
Bio-Path Holdings, a biotechnology firm, is set to present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:30 a.m. ET. CEO Peter H. Nielsen will lead the presentation. The company specializes in developing targeted nucleic acid cancer drugs utilizing its proprietary DNAbilize™ technology. Its lead candidate, prexigebersen (BP1001), is in a Phase 2 study for blood cancers and is also under FDA consideration for solid tumors. Follow-up candidate BP1002 targets lymphoma and solid tumors.
Bio-Path Holdings (NASDAQ: BPTH) reported a net loss of $2.0 million for Q2 2020, an improvement from a $2.5 million loss in Q2 2019. R&D expenses decreased to $1.0 million from $1.5 million, while G&A expenses remained stable at $1.0 million. As of June 30, 2020, cash stood at $14.4 million, down from $20.4 million at year-end 2019. The company has initiated the first patient dosing in Stage 2 of its Phase 2 trial for prexigebersen in treating acute myeloid leukemia and plans to start a Phase 1 study for solid tumors by year-end.
Bio-Path Holdings (BPTH) reported Q1 2020 financial results, showing a net loss of $3.3 million, or $0.90 per share, compared to a loss of $1.5 million in Q1 2019. R&D expenses surged to $2.0 million due to clinical trial preparations. The company plans to initiate a Phase 2 safety trial for its lead candidate, prexigebersen, in AML. COVID-19 has limited site access but has not significantly impacted operations. Cash reserves stood at $17.9 million as of March 31, 2020.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a live conference call on May 15, 2020, at 8:30 a.m. ET, to discuss its financial results for Q1 ending March 31, 2020, and provide a business overview. The call can be accessed domestically at (844) 815-4963 or internationally at (210) 229-8838, using conference ID 7973458. The company's lead product, prexigebersen (BP1001), is currently in a Phase 2 study for blood cancers, with plans for Phase 1 studies in solid tumors pending FDA consideration.